Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 3
2004 3
2005 1
2006 8
2007 10
2008 11
2009 15
2010 18
2011 17
2012 7
2013 7
2014 8
2015 3
2017 4
2018 4
2019 10
2020 4
2021 3
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group. Martin M, et al. Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13. Lancet Oncol. 2017. PMID: 29146401 Clinical Trial.
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Lancet. 2019 Apr 6;393(10179):1440-1452. doi: 10.1016/S0140-6736(18)33137-4. Epub 2019 Feb 8. Lancet. 2019. PMID: 30739743 Free PMC article.
Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
Makrakis D, Rounis K, Tsigkas AP, Georgiou A, Galanakis N, Tsakonas G, Ekman S, Papadaki C, Monastirioti A, Kontogianni M, Gioulbasanis I, Mavroudis D, Agelaki S. Makrakis D, et al. Among authors: mavroudis d. PLoS One. 2023 Feb 10;18(2):e0277708. doi: 10.1371/journal.pone.0277708. eCollection 2023. PLoS One. 2023. PMID: 36763597 Free PMC article.
Expert Discussion: HER2-Positive Breast Cancer.
Foukakis T, Matikas A, Oikonomidou O, Andreopoulou E, Mavroudis D. Foukakis T, et al. Among authors: mavroudis d. Breast Care (Basel). 2021 Aug;16(4):422-428. doi: 10.1159/000516965. Epub 2021 Jun 17. Breast Care (Basel). 2021. PMID: 34602950 Free PMC article. No abstract available.
Circulating tumor cells in breast cancer.
Ignatiadis M, Georgoulias V, Mavroudis D. Ignatiadis M, et al. Among authors: mavroudis d. Curr Opin Obstet Gynecol. 2008 Feb;20(1):55-60. doi: 10.1097/GCO.0b013e3282f22b2e. Curr Opin Obstet Gynecol. 2008. PMID: 18197007 Review.
Paclitaxel and docetaxel in the treatment of breast cancer.
Saloustros E, Mavroudis D, Georgoulias V. Saloustros E, et al. Among authors: mavroudis d. Expert Opin Pharmacother. 2008 Oct;9(15):2603-16. doi: 10.1517/14656566.9.15.2603. Expert Opin Pharmacother. 2008. PMID: 18803448 Review.
Nuclear localization of PD-L1: artifact or reality?
Polioudaki H, Chantziou A, Kalyvianaki K, Malamos P, Notas G, Mavroudis D, Kampa M, Castanas E, Theodoropoulos PA. Polioudaki H, et al. Among authors: mavroudis d. Cell Oncol (Dordr). 2019 Apr;42(2):237-242. doi: 10.1007/s13402-018-00419-7. Epub 2019 Jan 25. Cell Oncol (Dordr). 2019. PMID: 30680705
117 results